12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa

12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa

Neurofibromatosis Type 1 (NF1 / von Recklinghausen Disease)

Neurofibromatosis Type 1 (NF1) is one of the most common autosomal dominant genodermatoses, affecting approximately 1 in 3,000 live births. Approximately 50% of cases arise from de novo spontaneous mutations.

Molecular Genetics & Pathogenesis

• Gene Defect: The NF1 gene is located on chromosome 17q11.2, encoding the 220–250 kDa protein neurofibromin.
• Signaling Pathway: Neurofibromin functions as a GTPase-activating protein (GAP) that accelerates the intrinsic hydrolysis of active, GTP-bound RAS into inactive, GDP-bound RAS. Loss-of-function NF1 mutations eliminate this critical negative regulatory brake, leading to constitutive hyperactivation of the RAS/MAPK and PI3K/Akt signaling cascades, driving aberrant cell proliferation and multiorgan tumorigenesis.

Revised International Consensus Diagnostic Criteria (Legius et al., 2021)

Diagnosis is formally established if at least 2 of the following criteria are met in an individual:

1. Café-au-Lait Macules (CALMs): ≥6 café-au-lait macules with greatest diameter >5 mm in prepubertal individuals or >15 mm in postpubertal individuals.
2. Intertriginous Freckling (Crowe Sign): Freckling localized to the axillary or inguinal vaults (small, 1–3 mm pigmented macules).
3. Neurofibromas: ≥2 neurofibromas of any type (cutaneous or subcutaneous) OR ≥1 plexiform neurofibroma.
4. Optic Pathway Glioma (OPG): Low-grade pilocytic astrocytoma of the optic nerve, chiasm, or tract.
5. Iris or Choroidal Lesions: ≥2 Lisch nodules (melanocytic iris hamartomas visualized by slit-lamp examination) OR ≥2 choroidal abnormalities (defined as bright, patchy, patchy nodules seen on near-infrared reflectance [NIR] imaging).
6. Distinctive Osseous Lesion: Sphenoid wing dysplasia, anterolateral bowing of the tibia (tibial pseudarthrosis), or thinning of long bone cortex.
7. Genetic Criterion: A heterozygous pathogenic NF1 variant with a variant allele fraction of 50% in apparently normal tissue such as white blood cells.

Under the 2021 revised criteria, a child of a parent who meets the NF1 criteria needs only one of the features above (rather than two).

Diagnostic Caveat (Legius Syndrome): An individual with only CALMs and intertriginous freckling may possess Legius syndrome (caused by germline mutations in SPRED1 on chromosome 15q14). Legius syndrome lacks neurofibromas, Lisch nodules, central nervous system tumors, and bone dysplasia.

Spectrum of Neurofibromas & Malignancy Risks

• Cutaneous Neurofibromas: Soft, flesh-colored to violaceous, dome-shaped or pedunculated papules displaying pathognomonic "buttonholing" (invagination into the cutis upon gentle fingertip pressure). Emerge during puberty and increase during pregnancy. Possess zero malignant potential.
• Subcutaneous Neurofibromas: Firm, tender, nodular masses along peripheral nerve branches in the deep dermis and hypodermis.
• Plexiform Neurofibromas: Congenital, diffuse nerve-sheath neoplasms growing along nerve plexuses, characteristically feeling like a "bag of worms" on palpation. Often surmounted by hyperpigmented, hypertrichotic skin. People with NF1 have an 8% to 13% lifetime risk of highly aggressive Malignant Peripheral Nerve Sheath Tumours (MPNST), which usually arise in plexiform or atypical neurofibromas. Warning signs of malignant degeneration: rapid enlargement, new-onset persistent unremitting pain, and newly developed motor/sensory deficits.
• Targeted Therapy: Selumetinib (an oral, selective MEK1/MEK2 inhibitor) is approved in the EU for children aged 3 years and older with symptomatic, inoperable plexiform neurofibromas (the US label starts at age 2; check current labelling for adults), producing substantial tumor volume shrinkage and pain reduction.

Non-Cutaneous Manifestations & Surveillance

• Cardiovascular: Routine blood pressure screening at every visit is mandatory. Hypertension mandates exclusion of renal artery stenosis (secondary to fibromuscular dysplasia) in children or pheochromocytoma in adolescents and adults.
• Ophthalmologic: Annual screening with formal visual acuity testing until age 8 to detect asymptomatic optic pathway gliomas before vision loss occurs.
• Orthopedic: Anterolateral tibial bowing presents in infancy; minor trauma can induce non-union fractures (pseudarthrosis).

---

Tuberous Sclerosis Complex (TSC / Bourneville Disease)

Tuberous Sclerosis Complex (TSC) is an autosomal dominant neurocutaneous disorder affecting 1 in 6,000 to 10,000 individuals, characterised by widespread hamartomatous growths in the brain, skin, eyes, kidneys, heart, and lungs. Approximately two-thirds of cases arise from de novo spontaneous mutations.

Molecular Genetics & Pathogenesis

• Gene Defects: Heterozygous mutations in either TSC1 (chromosome 9q34, encoding hamartin) or TSC2 (chromosome 16p13.3, encoding tuberin). TSC2 mutations account for ~75% of sporadic cases and typically produce a more severe clinical phenotype.
• Signaling Pathway: Hamartin and tuberin form a cytosolic heterodimeric complex that functions as a GTPase-activating protein for the small GTPase Rheb. Inactivation of the TSC1-TSC2 complex allows GTP-loaded Rheb to stimulate the mechanistic target of rapamycin complex 1 (mTORC1). Unchecked mTORC1 hyperactivation drives unrestrained downstream protein translation (via p70S6 kinase and 4E-BP1), ribosomal biogenesis, vascular proliferation, and hamartoma formation.

International Diagnostic Criteria (2021 Revision)

Definite TSC is established by the presence of 2 major features OR 1 major feature + ≥2 minor features, OR identification of a pathogenic TSC1 or TSC2 mutation:

Major Features

1. Hypomelanotic Macules: ≥3 macules, at least 5 mm in diameter (classic "ash-leaf" lanceolate or polygonal macules, best detected under Wood's lamp examination).
2. Angiofibromas (≥3) or Fibrous Cephalic Plaque: Facial angiofibromas (historically misnamed adenoma sebaceum) present as 1–4 mm pink-red, telangiectatic, dome-shaped papules distributed symmetrically across the nasolabial folds, cheeks, and chin. Cephalic plaques present as firm, leathery, flesh-colored to red-brown plaques on the forehead.
3. Ungual Fibromas (≥2, Koenen Tumours): Smooth, firm, fleshy periungual or subungual nodules emerging from the nail groove, typically during adolescence.
4. Shagreen Patch: A connective tissue naevus (collagenoma) manifesting as an indurated, soft, yellowish-orange to flesh-colored pebbled plaque resembling "orange peel" or cobblestone leather, classically located over the lumbosacral region.
5. Multiple Retinal Hamartomas (Phakomas): Mulberry-like retinal calcifications.
6. Cortical Dysplasias: Cortical tubers and cerebral white-matter radial migration lines.
7. Subependymal Nodules (SEN): Benign hamartomatous nodules along ventricular walls.
8. Subependymal Giant Cell Astrocytoma (SEGA): Slowly growing astrocytic tumor near the foramen of Monro, risking acute obstructive hydrocephalus.
9. Cardiac Rhabdomyoma: Frequently detected on prenatal ultrasound or in neonates; typically undergoes spontaneous involution during the first few years of life.
10. Lymphangioleiomyomatosis (LAM): Diffuse cystic pulmonary destruction occurring almost exclusively in adult females, presenting with dyspnea and spontaneous recurrent pneumothoraces.
11. Renal Angiomyolipomas (AML, ≥2): Benign triphasic mesenchymal tumors (smooth muscle, fat, thick-walled vessels). Lesions >4 cm carry a high risk of aneurysmal rupture and catastrophic retroperitoneal haemorrhage (Wunderlich syndrome).

Minor Features

• "Confetti" skin lesions (multiple tiny 1–3 mm hypopigmented macules).
• Dental enamel pits (≥3 pits scattered on tooth surfaces).
• Intraoral fibromas (≥2).
• Retinal achromic patch.
• Multiple renal cysts.
• Non-renal hamartomas.
• Sclerotic bone lesions.

Targeted Pharmacotherapy: mTOR Inhibitors

• Topical Sirolimus (Rapamycin) 0.1% to 1% Gel/Ointment: First-line non-surgical treatment for facial angiofibromas. Directly suppresses mTORC1 hyperactivation, significantly decreasing erythema, vascularity, and papular size without systemic toxicity.
• Oral Everolimus: EU-approved for subependymal giant cell astrocytomas (SEGA) not suitable for surgery, renal angiomyolipomas at risk of complications (growing lesions of about 3 cm or more), and refractory focal seizures in TSC.
• Oral Sirolimus: The mTOR inhibitor recommended for progressive pulmonary lymphangioleiomyomatosis (LAM).

---

Xeroderma Pigmentosum (XP)

Xeroderma Pigmentosum (XP) is a rare autosomal recessive genodermatosis characterised by severe cellular hypersensitivity to ultraviolet radiation (UVR), premature actinic damage, early cutaneous carcinogenesis, and progressive neurodegeneration.

Molecular Pathogenesis: Nucleotide Excision Repair (NER)

• The NER Pathway: The primary DNA repair mechanism responsible for excising bulky, helix-distorting photolesions induced by solar UV radiation—predominantly cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4 PPs).
• Genetic Complementation Groups: Seven classic complementation groups (XPA through XPG) represent sequential enzymatic components of the NER machinery:
  • Global Genome NER (GG-NER): Detects damage across the entire genome (XPC, XPE/DDB2).
  • Transcription-Coupled NER (TC-NER): Repairs damage on actively transcribed DNA strands (CSA, CSB).
  • Core Repair Complex: DNA unwinding by helicases (XPB, XPD), dual 5' and 3' endonucleolytic excision of damaged oligonucleotides (XPF/ERCC1, XPG), and resynthesis by DNA polymerase (XPA serves as the scaffolding coordinator).
• XP Variant (XP-V): Represents approximately 20% of cases, caused by mutations in POLH encoding DNA polymerase eta (Pol η). Pol η mediates error-free translesion DNA synthesis past unexcised thymine dimers. In XP-V, classical NER is intact, but replication across UV photolesions falls to error-prone bypass polymerases (Pol ι, Pol ζ), introducing high frequencies of transitional mutations.

Clinical Presentation and Natural History

• Acute Sun Hypersensitivity (Infancy): In ~60% of cases (especially XP-A, XP-B, XP-D), minimal sun exposure induces severe, blistering, persistent sunburns out of proportion to exposure with prolonged erythema lasting weeks.
• Pigmentary Changes: By age 2, dense, diffuse, freckle-like lentigines and hyperpigmented macules emerge across sun-exposed skin (face, neck, dorsum of hands), accompanied by xerosis and telangiectasias.
• Cutaneous Neoplasia: Affected individuals have a >10,000-fold increased risk of non-melanoma skin cancer (BCC and SCC) and a >2,000-fold increased risk of cutaneous melanoma under age 20. The median age of onset for the first skin cancer is approximately 8 to 9 years (compared to 60+ years in the general population). Basal cell carcinomas, aggressive squamous cell carcinomas, and lentigo maligna melanomas arise repeatedly.
• Ophthalmic Hallmarks: Severe photophobia, chronic conjunctival injection, dry eye syndrome, corneal neovascularisation, keratitis, pterygium, ectropion, and ocular surface squamous neoplasia (corneal and conjunctival SCC).
• Neurological Degeneration (20% to 30% of Patients): Most prevalent in XP-A, XP-B, XP-D, and XP-G (De Sanctis-Cacchione syndrome). Manifests with progressive intellectual disability, sensorineural hearing loss, progressive microcephaly, cerebellar ataxia, loss of deep tendon reflexes, and choreoathetosis due to neuronal apoptosis from unexcised endogenous oxidative DNA damage.

Management & Prevention

• Rigorous Photoprotection: Strict, lifelong elimination of UV exposure: UV-absorbing films on domestic and vehicle windows, broad-brimmed hats, UV-blocking face shields, sun-protective clothing, and daily broad-spectrum SPF 50+ sunscreens (reapplied every 2 hours).
• Chemoprevention: Oral acitretin (0.5–1 mg/kg/day) significantly reduces the incidence of new non-melanoma skin cancers; however, rebound tumor emergence occurs upon discontinuation.
• Surveillance: Comprehensive full-body dermatologic examination every 3 months; prompt surgical excision or cryotherapy of premalignant actinic keratoses and carcinomas.

---

Inherited Epidermolysis Bullosa (EB) Spectrum

Inherited Epidermolysis Bullosa (EB) comprises a group of rare genetic disorders characterised by extreme mechanical fragility of the skin and mucous membranes, where minimal lateral friction or trauma produces blistering and erosions.

Consensus Classification by Cleavage Level

The international consensus classification defines four major types based on the ultrastructural level of tissue separation across the dermo-epidermal junction (DEJ):

Epidermis [Keratin 5 / Keratin 14]       -->  EB SIMPLEX (EBS)  [Intraepidermal cleavage]
-----------------------------------------------------------------------------------------
Lamina Lucida [Laminin-332, BP180/Col17] -->  JUNCTIONAL EB (JEB) [Intra-lamina lucida]
-----------------------------------------------------------------------------------------
Lamina Densa [Type IV Collagen]
-----------------------------------------------------------------------------------------
Sub-Lamina Densa [Type VII Collagen]     -->  DYSTROPHIC EB (DEB) [Sub-lamina densa]

1. Epidermolysis Bullosa Simplex (EBS)

• Cleavage Level: Intraepidermal (within basal keratinocytes).
• Molecular Genetics: Autosomal dominant (rarely autosomal recessive) mutations in KRT5 (chromosome 12q) or KRT14 (chromosome 17q). Mutations in PLEC (plectin) cause EBS with muscular dystrophy or pyloric atresia; KLHL24, DST.
• Major Subtypes:
  • Localized EBS (Weber-Cockayne): The most common EB subtype. Blistering is restricted to areas of mechanical friction on the palms and soles, typically exacerbated by warm weather and sweating. Onset in late childhood or adolescence. Blisters heal without scarring and without milia.
  • Intermediate EBS (Koebner): Generalized blistering over hands, feet, and extremities.
  • Severe EBS (Dowling-Meara): Manifests at birth with extensive, grouped, herpetiform blisters, nail shedding, and oral mucosal erosions. Characterised by spiny palmoplantar keratoderma in childhood and dense tonofilament clumping on electron microscopy.

2. Junctional Epidermolysis Bullosa (JEB)

• Cleavage Level: Intra-lamina lucida of the basement membrane zone.
• Molecular Genetics: Biallelic mutations in LAMA3, LAMB3, or LAMC2 (encoding the heterotrimeric adhesion molecule Laminin-332, formerly laminin-5); COL17A1 (encoding Type XVII Collagen / Bullous Pemphigoid Antigen 2 / BP180); or ITGA6 / ITGB4 (alpha-6 beta-4 integrin).
• Major Subtypes:
  • Generalized Severe JEB (Herlitz JEB): Caused by biallelic null mutations in laminin-332 genes. Typically lethal in infancy (median survival <1 year). Hallmarks include widespread blistering, intractable de-epithelialized erosions, exuberant bright-red granulation tissue around the mouth, nose, and nail folds, nail shedding, severe laryngeal blistering producing a hoarse, weak cry, failure to thrive, and respiratory death.
  • Generalized Intermediate JEB (Non-Herlitz): Caused by missense COL17A1 or laminin-332 mutations. Compatible with adulthood; characterised by generalized blistering, severe enamel hypoplasia (pitted dental enamel), progressive cicatricial alopecia, and dystrophic nails.
  • JEB with Pyloric Atresia: Caused by mutations in ITGA6 or ITGB4; neonates present with generalized blistering and congenital gastric outlet obstruction.

3. Dystrophic Epidermolysis Bullosa (DEB)

• Cleavage Level: Sub-lamina densa in the uppermost papillary dermis (level of anchoring fibrils).
• Molecular Genetics: All forms of DEB are caused exclusively by mutations in COL7A1 (chromosome 3p21.3) encoding Type VII Collagen, the principal structural constituent of anchoring fibrils that anchor the lamina densa to dermal collagen fibres.
• Major Subtypes:
  • Dominant DEB (DDEB): Typically caused by heterozygous glycine substitutions in the triple-helical domain of collagen VII. Blistering is predominantly acral over elbows, knees, and knuckles. Blisters heal with scarring and milia formation; dystrophic or lost toenails/fingernails; albopapuloid lesions of Pasini (white scar-like papules on the trunk).
  • Generalized Severe Recessive DEB (RDEB / Hallopeau-Siemens): Caused by biallelic null mutations producing a complete absence of Type VII Collagen and anchoring fibrils. The most devastating chronic form of EB:
    1. Extremity Mutilation: Repetitive blistering, deep ulceration, and fibrosis cause digital fusion and progressive web-space obliteration, culminating in classic "mitten deformities" (pseudosyndactyly) of hands and feet with joint contractures.
    2. Gastrointestinal Strictures: Blistering of the oral and esophageal mucosa produces microstomia, ankyloglossia, and severe esophageal strictures requiring serial endoscopic balloon dilatations or gastrostomy feeding.
    3. Systemic Complications: Refractory iron-deficiency anemia, severe growth retardation, osteopenia, and renal amyloidosis.
    4. Malignancy: Aggressive Cutaneous Squamous Cell Carcinoma (SCC) arising within chronic, unhealed wounds. Cumulative risk of developing SCC exceeds 70% to 80% by age 45. These carcinomas are unusually invasive, highly metastatic, and represent the leading cause of death in RDEB.

4. Kindler EB (Kindler Syndrome)

• Cleavage Level: Mixed / multiple cleavage levels (intraepidermal, lamina lucida, and sub-lamina densa can all occur in the same specimen).
• Molecular Genetics: Autosomal recessive mutations in FERMT1 (encoding kindlin-1, an actin-cytoskeleton focal adhesion protein).
• Clinical Presentation: Neonatal trauma-induced blistering and marked cutaneous photosensitivity. In childhood, blistering diminishes while progressive poikiloderma (mottled hyper- and hypopigmentation, telangiectasias), severe parchment-like skin atrophy ("cigarette paper skin"), and urethral/anal mucosal stenosis develop.

Diagnostic Workflow & Novel Targeted Therapeutics

1. Diagnostic Biopsy: A fresh, mechanically induced blister must be obtained from normal-appearing skin via gentle pencil-eraser friction.
2. Antigen Mapping (IFM) & Electron Microscopy (TEM): Immunofluorescence mapping using monoclonal antibodies against K14, laminin-332, collagen IV, and collagen VII rapidly determines the cleavage plane. Transmission electron microscopy provides ultrastructural visualization of hemidesmosomes and anchoring fibrils.
3. Genetic Confirmation: Next-Generation Sequencing (NGS) multigene panels.
4. Therapeutic Breakthroughs:
   • Beremagene Geperpavec (B-VEC): A topical, redosable, replication-incompetent herpes simplex virus type 1 (HSV-1) vector engineered to deliver full-length human COL7A1 cDNA directly to open wounds in DDEB and RDEB, promoting sustained wound closure and collagen VII restoration.
   • Wound Care: Non-adherent silicone and lipidocolloid dressings; avoidance of adhesive tapes; prevention of hand mitten deformities through daily interdigital wrapping.